Home > Insider Trading > Filing (0001477932-21-003575)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1643301	Cure Pharmaceutical Holding Corp.	CURR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1412747	Steven Robert Davidson	1620 Beacon Place Oxnard CA 93022	Chief Executive Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2018-10-10	25,000	$0.00	524,756	No	4	G	Direct
Common Stock	Acquisiton	2019-07-01	31,250	$0.00	556,006	No	4	A	Direct
Common Stock	Acquisiton	2021-05-24	6,443	$0.69	562,449	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	G	Direct
No	4	A	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option	Acquisiton	2016-11-07	354,000	$0.00	354,000	$0.74
Common Stock	Stock Option	Acquisiton	2018-05-07	68,750	$0.00	68,750	$0.61
Common Stock	Stock Option	Acquisiton	2019-04-11	225,000	$0.00	225,000	$3.40

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
354,000	2028-04-06	No	4	A	Direct
68,750	2028-05-07	No	4	A	Direct
225,000	2029-04-11	No	4	A	Direct

Footnotes

The reporting person transferred 25,000 shares of common stock to his son as a bona-fide gift. This late filing is due to an inadvertent administrative error and not any error of the reporting person.
Represents shares of common stock received upon vesting of a restricted stock award. This late filing is due to an inadvertent administrative error and not any error of the reporting person.
This is the weighted average purchase price. Shares were purchased in multiple transactions at prices from $0.68422 to $0.69350. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. The amount reflected has been rounded to 3 decimal points.
The option becomes exercisable on the basis determined by the equity incentive plan with 6.25% of the option vesting on the first quarter anniversary of vesting start date. For each additional quarter of the participant's service the option will continue to vest until the vested ratio is 100%. This late filing is due to an inadvertent administrative error and not any error of the reporting person.